OCUP Ocuphire Pharma
- 1.650
- +0.040+2.48%
- 1.690
- +0.040+2.42%
Ocuphire Pharma News
Press Release: Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) ("Ocuphire"), a clinical-st
Ocuphire Pharma Incentivizes Director Pepose With Stocks and Options
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOntrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday's after-market session. The company's market cap stands at $18.9 million. Ocuphire Pharma (NASDAQ:OCUP) stock rose 7.82%
Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment
Ocuphire Pharma (OCUP) enrolled the first patient in the phase 3 trial of its Phentolamine Ophthalmic Solution 0.75% for the treatment of decreased visual acuity under low light conditions following k
Express News | First Patient Enrolled in Lynx-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (Ps) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN), Ocuphire Pharma (OCUP) and Vertex Pharmaceuticals (VRTX)
Ocuphire Announces the US Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by Its Partner Viatris
Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disor
Ocuphire Pharma Engages Investors With Presentation Update
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders int
Ocuphire Pharma(OCUP.US) Officer Buys US$4,100 in Common Stocks
$Ocuphire Pharma(OCUP.US)$ Officer SCHACHLE JOSEPH K purchased 2,000 shares of Common Stocks on Mar 21, 2024 at an average price of $2.05 for a total value of $4,100.Source: Announcement What is state
Ocuphire Pharma(OCUP.US) Officer Buys US$21,000 in Common Stocks
$Ocuphire Pharma(OCUP.US)$ Officer Jhaveri Nirav S. purchased 10,000 shares of Common Stocks on Mar 21, 2024 at an average price of $2.1 for a total value of $21,000.Source: Announcement What is state
Ocuphire Pharma(OCUP.US) Officer Buys US$49,050 in Common Stocks
$Ocuphire Pharma(OCUP.US)$ Officer Magrath George purchased 25,000 shares of Common Stocks on Mar 18, 2024 at an average price of $1.962 for a total value of $49,050.Source: Announcement What is state
Ocuphire Pharma Is Maintained at Buy by Alliance Global Partners
Ocuphire Pharma Is Maintained at Buy by Alliance Global Partners
Alliance Global Partners Maintains Buy on Ocuphire Pharma, Lowers Price Target to $20
Alliance Global Partners analyst James Molloy maintains Ocuphire Pharma with a Buy and lowers the price target from $24 to $20.
Earnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their Forecasts
Express News | HC Wainwright & Co. Reiterates Buy on Ocuphire Pharma, Maintains $20 Price Target
Ocuphire Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/11/2024 895.02% HC Wainwright & Co. → $20 Reiterates Buy → Buy 11/14/2023 895.02% HC Wainwright & Co. →
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Merus (MRUS) and Eli Lilly & Co (LLY)
Buy Rating Affirmed for Ocuphire Pharma on Promising APX3330 Progress for Diabetic Retinopathy Treatment
Ocuphire Pharma Full Year 2023 Earnings: Misses Expectations
Analysis
Price Target
No Data
